Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY900014 vs Insulin Lispro in Japanese T1DM
NCT03407118Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2018
- Primary completion
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin lispro in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Insulin Lispro Area Under the Concentration Curve Zero to 10 Hours. Started Feb 2018; status: completed.
02
Drugs
insulin lispro
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03407118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03407118.